AstraZeneca PLC (AZN)AZNAstraZeneca PLC

Balance Sheet

Assets, liabilities, and equity analysis

Quarterly Balance Sheet (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024	Quarter ended Jun 2024
Total Current Assets	29.61B	29.61B	28.72B	29.94B	28.94B	26.14B	25.83B	24.16B	25.39B
Cash & Cash Equivalents	7.56B	7.56B	5.71B	8.14B	7.06B	5.23B	5.49B	4.80B	6.92B
Short-Term Investments	115.00M	115.00M	30.00M	39.00M	50.00M	165.00M	166.00M	133.00M	160.00M
Cash & Short-Term Investments	7.67B	7.67B	5.74B	8.18B	7.11B	5.39B	5.65B	4.93B	7.08B
Accounts Receivable	14.11B	14.11B	15.18B	14.34B	14.17B	13.25B	12.97B	11.88B	11.05B
Inventory	6.57B	6.57B	6.56B	6.59B	6.47B	5.88B	5.29B	5.66B	5.67B
Total Assets	114.02B	114.02B	114.07B	114.46B	112.42B	106.25B	104.03B	104.92B	104.34B
Property, Plant & Equipment	14.94B	14.94B	14.70B	13.78B	13.23B	12.30B	11.65B	11.51B	10.83B
Goodwill	21.19B	21.19B	21.24B	21.22B	21.22B	21.13B	21.02B	21.14B	21.06B
Intangible Assets	36.91B	36.91B	37.85B	38.19B	37.92B	37.55B	37.18B	39.39B	39.43B
Long-Term Investments	4.24B	4.24B	2.52B	2.29B	4.85B	1.90B	1.73B	2.01B	0.00
Total Current Liabilities	32.57B	32.57B	30.62B	34.05B	33.54B	29.13B	27.87B	25.93B	28.57B
Accounts Payable	22.50B	22.50B	25.28B	25.03B	23.99B	22.54B	22.46B	21.68B	20.46B
Short-Term Debt	7.58B	7.58B	3.19B	6.20B	6.49B	3.42B	2.16B	1.25B	5.07B
Total Liabilities	66.63B	66.63B	65.36B	68.48B	67.61B	65.12B	63.16B	64.12B	64.74B
Long-Term Debt	24.45B	24.45B	24.71B	24.70B	24.71B	26.74B	26.51B	28.89B	27.23B
Total Debt	33.92B	33.92B	29.70B	32.66B	32.84B	31.72B	30.11B	31.56B	33.53B
Net Debt (Cash)	26.36B	26.36B	23.99B	24.52B	25.78B	26.49B	24.63B	26.77B	26.62B
Total Shareholders' Equity	47.33B	47.33B	48.67B	45.89B	44.72B	41.04B	40.79B	40.72B	39.51B
Common Stock	388.00M	388.00M	388.00M	388.00M	388.00M	388.00M	388.00M	388.00M	388.00M
Retained Earnings	9.67B	9.67B	10.97B	8.21B	7.02B	3.36B	3.16B	3.14B	1.85B
Current Ratio	0.91	0.91	0.94	0.88	0.86	0.90	0.93	0.93	0.89
Debt to Equity Ratio	0.72	0.72	0.61	0.71	0.73	0.77	0.74	0.78	0.85

Annual Balance Sheet (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Total Current Assets	28.72B	25.83B	25.05B	22.59B	26.24B	19.54B	15.56B	15.59B
Cash & Cash Equivalents	5.71B	5.49B	5.84B	6.17B	6.33B	7.83B	5.37B	4.83B
Short-Term Investments	30.00M	37.00M	20.00M	77.00M	69.00M	160.00M	849.00M	849.00M
Cash & Short-Term Investments	5.74B	5.53B	5.86B	6.24B	6.40B	7.99B	6.22B	5.68B
Accounts Receivable	15.18B	11.23B	8.41B	9.19B	8.13B	5.65B	4.90B	3.00B
Inventory	6.56B	5.29B	5.42B	4.70B	8.98B	4.02B	3.19B	2.89B
Total Assets	114.07B	104.03B	101.12B	96.48B	105.36B	66.73B	61.38B	60.65B
Property, Plant & Equipment	14.70B	11.65B	10.50B	9.45B	10.17B	8.92B	8.34B	7.42B
Goodwill	21.24B	21.02B	20.05B	19.82B	20.00B	11.85B	11.67B	11.71B
Intangible Assets	37.85B	37.18B	38.09B	39.31B	42.39B	20.95B	20.83B	21.96B
Long-Term Investments	2.52B	0.00	1.78B	0.00	0.00	0.00	0.00	113.00M
Total Current Liabilities	30.62B	27.87B	30.54B	26.29B	22.59B	20.31B	18.12B	16.29B
Accounts Payable	25.28B	3.64B	3.27B	2.55B	2.82B	2.35B	1.77B	1.72B
Short-Term Debt	3.19B	2.16B	5.13B	5.22B	1.57B	2.19B	1.82B	1.78B
Total Liabilities	65.36B	63.16B	61.95B	59.42B	66.08B	51.09B	46.78B	46.61B
Long-Term Debt	24.71B	26.51B	22.36B	22.96B	28.13B	17.50B	15.73B	19.20B
Total Debt	29.70B	30.11B	28.62B	29.14B	30.69B	20.38B	18.23B	19.11B
Net Debt (Cash)	23.99B	24.63B	22.78B	22.98B	24.36B	12.55B	12.86B	14.28B
Total Shareholders' Equity	48.67B	40.79B	39.14B	37.04B	39.27B	15.62B	13.13B	12.47B
Common Stock	388.00M	388.00M	388.00M	387.00M	387.00M	328.00M	328.00M	317.00M
Retained Earnings	10.97B	3.16B	4.52B	-574.00M	1.71B	5.30B	2.81B	5.68B
Current Ratio	0.94	0.93	0.82	0.86	1.16	0.96	0.86	0.96
Debt to Equity Ratio	0.61	0.74	0.73	0.79	0.78	1.30	1.39	1.53

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.

About AstraZeneca PLC

AstraZeneca PLC operates as a global biopharmaceutical leader, dedicated to the entire process of bringing prescription medicines to market, from their initial discovery and development through manufacturing and commercialization. The company's extensive portfolio of treatments, including prominent examples like Tagrisso, Farxiga, and Symbicort, addresses critical areas such as cardiovascular, renal, metabolic, and oncological conditions. Furthermore, it provides essential solutions for COVID-19 and various rare diseases, with products like Vaxzevria and Soliris. AstraZeneca engages with primary and specialty care physicians worldwide, facilitating distribution through a robust network of representatives and local offices across the United Kingdom, continental Europe, the Americas, Asia, Africa, and Australasia. The firm actively drives innovation through strategic collaborations, partnering with entities such as Neurimmune AG for the development and commercialization of NI006, BenevolentAI for systemic lupus erythematosus drug discovery, Lunit for AI-powered digital pathology risk assessment in NSCLC, and Absci Corporation for AI-driven oncology target identification. Founded in 1992, the company was initially known as Zeneca Group PLC, subsequently rebranding to AstraZeneca PLC in April 1999, and maintains its headquarters in Cambridge, United Kingdom.

Cambridge, CA

96,100 employees

www.astrazeneca.com

Healthcare / Drug Manufacturers - General

Sector: Healthcare
Industry: Drug Manufacturers - General
CEO: Pascal Claude Roland Soriot

View full financials